State laws mandating clinical trial reimbursement
We describe the extent to which existing CCC plans address disparities in clinical trials and, of the plans that do address the issue, which ones come from jurisdictions with third-party reimbursement laws.Back to top From April through December 2007, we analyzed CCC plans available on the Web sites Cancer Control PLANET (Plan, Link, Act, Network with Evidence-based Tools) (cancercontrolplanet.cancer.gov/state_plans.jsp) and Cancer (Results Fifty-five (96%) CCC plans had content regarding clinical trials.
All CCC plans were in Adobe Acrobat Portable Document Format (.pdf) (Adobe Systems, Inc, San Jose, California), which allowed us to search each plan using keywords. In step 1, we identified the CCC plans that addressed clinical trials by searching for “clinical trial(s),” randomized trial(s), clinical research, treatment trial(s), investigational therapy, or experimental treatment.
Back to top Knowledge gained through clinical trials has been critical to preventing, diagnosing, and treating cancer.
However, not all cancer patients benefit equally from these improvements.
Through the CCC planning process, various stakeholders, including those representing health departments, national organizations, universities, and local organizations, are brought into a statewide coalition to agree to local priorities and goals and to promote the plan among the stakeholders.
These plans provide a basic, initial indicator of how each jurisdiction proposes to address their particular burden of cancer, including addressing disparities in cancer clinical trials.
Other adult populations, such as those living in rural areas (4), those who are low income (5), or those without health insurance or third-party reimbursement for clinical trials (5), are also less likely to participate.